Phase II study evaluating the safety and efficacy of neoadjuvant leuvectin immunotherapy for the treatment of prostate cancer
Phase of Trial: Phase II
Latest Information Update: 20 Aug 2014
At a glance
- Drugs Leuvectin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Vical
- 31 Aug 2018 Biomarkers information updated
- 28 Jul 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record..
- 29 Sep 2005 New trial record.